<DOC>
	<DOC>NCT01371708</DOC>
	<brief_summary>This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with Major Depressive Disorder (MDD).</brief_summary>
	<brief_title>A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Completed study B2061032 and who in the investigator's opinion, would benefit from long term treatment with DVS SR Willingness and ability to comply with scheduled visits, treatment plan, and procedures Requires precaution against suicide Not in generally healthy medical condition Poor compliance with study drug or study procedures during participation in study B2061032</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>Depression</keyword>
</DOC>